Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Krka Enjoys ‘Strongest’ Half Year, Although Prescription Stagnates

Slovenian Firm Publishes Preliminary Results

Executive Summary

Having picked up five prescription marketing authorization approvals in the first half of 2021, Slovenian generics giant Krka will be hoping to build on stagnant prescription pharmaceuticals reported in preliminary financial results.

You may also be interested in...



Krka’s Zytiga Rival Wins CHMP Nod

Krka’s generic version of Janssen’s Zytiga has garnered a positive opinion from the EMA’s CHMP, along with Pinax Pharma’s Celsunax ioflupane generic of DaTSCAN and Nova Laboratories’ hybrid Jayempi azathioprine oral suspension.

Small Cash Component Delaying Opioid Deal, Says ‘Optimistic’ Teva

Teva CEO Kåre Schultz has spoken at great length and in great detail about Teva’s ability to reach a proposed settlement in the US over allegations the firm helped fuel the opioid epidemic, revealing that a deal may be only 12 months away.

Teva Likes Biosimilar Licensing Deals As It Cuts Full-Year Sales Guidance

Teva is keeping a keen eye out for opportunities like its US biosimilars agreement with Alvotech and more recent deal with Bioeq for biosimilar Lucentis as it attempts to maintain revenues in the coming years, following a cut to full-year sales guidance for 2021.

Topics

Related Companies

UsernamePublicRestriction

Register

GB151105

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel
;